OpenScience.ink

4 days ago • Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Glucagon-like peptide-1 receptor drugs and their link to diabetic eye disease: a review of outcomesGlucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes.

📖 Top 20% JournalArticle

5 days ago • Molecular neurobiology

Multiple Potential Treatments Using GLP-1 and GIP Receptor Activators for Spinal Cord InjuryThe Pleiotropic Therapeutic Perspectives of GLP-1 and GIP Receptor Agonists in Spinal Cord Injury: A Narrative Review.

🎖️ Top 10% JournalArticle

5 days ago • Therapeutic advances in endocrinology and metabolism

Tirzepatide's effects on heart health beyond blood sugar controlBeyond glycemic control: clinical cardiovascular effects of tirzepatide-a narrative review.

🎖️ Top 10% JournalArticle

5 days ago • Journal of the American Heart Association

Heart Effects of Glucagon Receptor Signals Alone and With Glucagon-Like Peptide-1 Signals in Multi-Target DrugsCardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.

🥉 Top 5% JournalArticle

6 days ago • Obesity (Silver Spring, Md.)

Testing oral GLP-1RA TERN-601 in adults with obesity or overweight: early phase placebo-controlled studies with increasing dosesOral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies.

🎖️ Top 10% JournalArticle

6 days ago • Obesity pillars

Nutrition advice for glucagon-like peptide treatments: Consensus from Asian Indian expertsNutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation.

📖 Top 20% JournalArticle

6 days ago • Lancet (London, England)

Effectiveness and safety of once-weekly injected zenagamtide, a new drug targeting blood sugar and appetite hormones, in type 2 diabetesEfficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.

🥇 Top 1% JournalArticle

6 days ago • RMD open

Starting tirzepatide and biologic treatments together improves patient-reported outcomes in obese psoriatic arthritisConcurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study.

🎖️ Top 10% JournalArticle

6 days ago • Regulatory toxicology and pharmacology : RTP

40-week safety, body processing, and immune response to repeated doses of efsubaglutide alfa under the skin in monkeys40-week repeat-dose toxicity, toxicokinetics, and immunogenicity of efsubaglutide alfa following subcutaneous administration in cynomolgus monkeys.

📖 Top 20% JournalArticle

6 days ago • Metabolism: clinical and experimental

Genetic evidence shows higher GLP-1 and lower GIP levels may have combined benefits for body weight and heart metabolismComplementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.

🥈 Top 2% JournalArticle